Clinical Trials Browser

Pancreatic Intraductal Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07114601 2026-06-03

OMNIRAY

Phase 1 Recruiting

421 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07214662 2026-06-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Phase 1 Recruiting

136 enrolled

Breast

Breast Neoplasms

NCT07222267 2026-06-03

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Phase 1 Recruiting

86 enrolled

Breast

Breast Neoplasms

NCT07310420 2026-06-03

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 1 Recruiting

88 enrolled

Breast

Breast Neoplasms

NCT07311993 2026-06-03

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Phase 1 Recruiting

60 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07046923 2026-06-02

A Study of LY4175408 in Participants With Advanced Cancer

Phase 1 Recruiting

240 enrolled

BreastGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07524855 2026-06-02

HLD-0117

Phase 1 Recruiting

33 enrolled

Breast

Breast Neoplasms

NCT06533332 2026-05-29

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

36 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Liver Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT06678269 2026-05-28

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Phase 1 Recruiting

28 enrolled

Breast

Breast Neoplasms

NCT07137416 2026-05-28

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

36 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05989347 2026-05-22

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Phase 1 Recruiting

20 enrolled

Breast

Breast Neoplasms, Hyperinsulinism

NCT06465069 2026-05-22

NEXUS-01

Phase 1 Recruiting

420 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT07578571 2026-05-22

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Phase 1 Recruiting

175 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07593820 2026-05-22

Catherine

Phase 1 Recruiting

15 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT06246968 2026-05-20

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Phase 1 Recruiting

30 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06959537 2026-05-20

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1 Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT07334119 2026-05-20

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Phase 1 Recruiting

60 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07029399 2026-05-19

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

361 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07360314 2026-05-18

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Phase 1 Recruiting

138 enrolled

BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04969835 2026-05-15

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Phase 1 Recruiting

158 enrolled

BreastGenitourinaryGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Salivary Gland Neoplasms, Sarcoma

NCT05005403 2026-05-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Phase 1 Recruiting

694 enrolled

BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05372640 2026-05-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Phase 1 Recruiting

45 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05422794 2026-05-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1 Recruiting

57 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05673200 2026-05-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05877599 2026-05-13

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase 1 Recruiting

45 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms

NCT06673329 2026-05-13

Brodalumab in the Treatment of Immune-Related Adverse Events

Phase 1 Recruiting

11 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Mouth Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms

NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1 Recruiting

15 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT06638307 2026-05-12

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Phase 1 Recruiting

240 enrolled

Breast

Advanced Breast Cancer

NCT05872295 2026-05-08

IKS014 in Advanced Solid Tumors That Express HER2

Phase 1 Recruiting

165 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

260 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05283330 2026-04-30

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Phase 1 Recruiting

48 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Glioblastoma, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT04890613 2026-04-28

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Phase 1 Recruiting

52 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07261631 2026-04-28

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Phase 1 Recruiting

180 enrolled

BreastGastrointestinalSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06562192 2026-04-24

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Phase 1 Recruiting

162 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Phase 1 Recruiting

241 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06347068 2026-04-22

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Phase 1 Recruiting

42 enrolled

Breast

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT06949410 2026-04-22

HER2 Vaccine for Locally Advanced Breast Cancer

Phase 1 Recruiting

36 enrolled

Breast

Breast Neoplasms

NCT06430541 2026-04-21

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Phase 1 Recruiting

20 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT06586957 2026-04-21

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

150 enrolled

BreastGastrointestinalGynecologicThoracic

Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Uterine Diseases, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07020117 2026-04-21

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Phase 1 Recruiting

150 enrolled

BreastHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT07524322 2026-04-21

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Phase 1 Recruiting

63 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05208762 2026-04-20

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Phase 1 Recruiting

714 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06150664 2026-04-20

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Phase 1 Recruiting

85 enrolled

BreastDermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Hodgkin Disease, Melanoma, Triple Negative Breast Neoplasms

Clinical Trials

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

A Phase 1/1b Study of IAM1363 in HER2 Cancers

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

FiREBOLT

OMNIRAY

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

A Study of LY4175408 in Participants With Advanced Cancer

HLD-0117

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

NEXUS-01

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Catherine

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Brodalumab in the Treatment of Immune-Related Adverse Events

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

IKS014 in Advanced Solid Tumors That Express HER2

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

HER2 Vaccine for Locally Advanced Breast Cancer

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies